论文部分内容阅读
本文探索联合检测CEA、CA125、CYFRA21-1、NSE对肺癌诊断的临床应用价值。收集从在2005年1月到2009年1月在通化市铁厂卫生院住院并经病理证实的肺癌患者128例。同时测定CEA,CA125,CYFRA21-1,NSE。CEA是在腺癌中阳性率最高为53.84%,特异性是100%;CYFRA21-1是在鳞癌中阳性率最高为66.67%,特异性最高为94%;对小细胞肺癌敏感的NSE的阳性率为75%。特异性是60%;CA125在肺癌中的阳性率为61.90%;四项联合检测的总阳性率升高为91.40%,其中III期IV期肺癌的阳性检出率分别为88.23%和91.52%,均高于I期II期的阳性检出率。结论:联合检测CEA、CA125、CYFRA21-1、NSE可以起到互相补充的作用,从而明显提高肺癌的阳性检出率,且其阳性检出率随病情的进展而升高。
This article explores the clinical value of combined detection of CEA, CA125, CYFRA21-1, and NSE in the diagnosis of lung cancer. We collected 128 patients with lung cancer who were hospitalized in Tonghua City Ironworks Hospital from January 2005 to January 2009 and confirmed by pathology. Simultaneous determination of CEA, CA125, CYFRA21-1, NSE. The highest positive rate of CEA in adenocarcinoma is 53.84%, and the specificity is 100%. The highest positive rate of CYFRA21-1 is 66.67% in squamous cell carcinoma and the highest specificity is 94%; positive for NSE sensitive to small cell lung cancer. The rate is 75%. The specificity was 60%; the positive rate of CA125 in lung cancer was 61.90%; the total positive rate of four combined detections was increased to 91.40%, and the positive detection rates of stage III and stage IV lung cancer were 88.23% and 91.52%, respectively. Are higher than the positive detection rate of phase I phase II. Conclusions: Combined detection of CEA, CA125, CYFRA21-1, and NSE can complement each other and significantly increase the positive detection rate of lung cancer, and the positive detection rate increases with the progression of the disease.